+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Brain and Spinal Cord Cancer Market Research and Forecast, 2018-2023

  • ID: 4751464
  • Report
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Affichem
  • Bristol-Myers Squibb
  • Eli Lilly And Co.
  • Genzyme Corp.
  • GlaxoSmithKline Plc.
  • Ono Pharmaceutical Co.
  • MORE
Brain and spinal cord cancer market is expected to high growth during 2018-2023 due to high incidence rate of brain and spinal cord cancer in the US and rising demand for minimally invasive surgeries across the globe. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Epidemiology, and End Results (SEER) database for 2011 indicate that the combined incidence of primary invasive CNS tumors in the US is 6.4 per 100,000 persons per year, with an estimated mortality of 4.3 per 100,000 persons per year. Globally, approximately 260 thousand new cases of brain and other CNS tumors were diagnosed in the year 2015, with an estimated 190 thousand deaths. Many countries are performing research and developments for the treatment of the brain and spinal cord cancer across the globe. The European Organisation for Research and Treatment of Cancer (EORTC) randomly assigned 311 patients with low-grade gliomas to undergo either radiation or observation in the EORTC-22845 (MRC BR04) trial. On review of central pathology, about 25% of patients in the trial were reported to have high-grade tumors. Most of the control patients received radiation therapy at the time of progression.

The global brain and spinal cord cancers market is analysed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America market for brain and spinal cord is predicted to experience a high growth throughout the forecast period. North America is expected to be followed by Europe during the forecasted period. The rapid growth of these two regions can be attributed to the increasing number of brain and spinal cord cancer cases and rising development of new drugs and therapeutics in the next few years. In addition to this, the advancements in technology and the favourable government policies and initiatives are projected to strengthen brain and spinal cord cancer market in North America and Europe in the near future. The increasing contribution from China, India, and Japan and the rising investments for research and development activities are projected to encourage the growth of the brain and spinal cord cancer market in Asia Pacific during the forecasted period.

Some of the key vendors of the brain and spinal cord cancer across the globe are Bristol-Myers Squibb, Daiichi Sankyo, Eisai Co. Ltd., Eli Lilly And Co, Ge Healthcare, Genzyme Corporation, Merck & Co., Inc., Teva Pharmaceuticals, and so on. This companies identifies direct or indirect strategy and at the same time, it permits the collaboration of their mission, vision, core values, niche market, strengths and weaknesses to obtain a significant position in the market. This company is based on the development of new strategies that helps them to differentiate from the competition.

The Report Covers
  • Comprehensive research methodology of global brain and spinal cord cancer market.
  • This report also includes detailed and extensive market overview with analyst insights & key market trends.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global brain and spinal cord cancer market.
  • Insights about market determinants which are stimulating the global brain and spinal cord cancer market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Affichem
  • Bristol-Myers Squibb
  • Eli Lilly And Co.
  • Genzyme Corp.
  • GlaxoSmithKline Plc.
  • Ono Pharmaceutical Co.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Definition
2.2. Analyst & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Regulations
2.3.1. United States
2.3.2. European Union
2.3.3. China
2.3.4. India
2.3.5. Rest of The World

3. Market Determinant
3.1. Market Motivators
3.2. Restraints
3.3. Opportunities

4. Market Segmentation
4.1. Global Brain and Spinal Cord Cancer Market on the Basis of Type
4.1.1. Grade I
4.1.2. Grade Ii
4.1.3. Grade Iii
4.1.4. Grade Iv
4.2. Global Brain and Spinal Cord Cancer Market on the Basis of Diagnostic Test
4.2.1. Imaging Tests
4.2.2. Magnetic Resonance Imaging (MRI) Scan
4.2.3. Computed Tomography (CT) Scan
4.2.4. Positron Emission Tomography (Pet) Scan
4.2.5. Chest X-Ray
4.3. Global Brain and Spinal Cord Cancer Market on the Basis of Treatment
4.3.1. Surgery
4.3.2. Chemotherapy
4.3.3. Radiation Therapy
4.3.4. Targeted Therapy
4.3.5. Alternating Electric Field Therapy
4.3.6. Other

5. Competitive Landscape
5.1. Market Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia Pacific
6.4. Rest of The World

7. Company Profiles
7.1. Actinium Pharmaceuticals Inc.
7.2. Affichem
7.3. Biogen Idec Inc.
7.4. Bristol-Myers Squibb
7.5. Daiichi Sankyo
7.6. Eli Lilly And Co.
7.7. Ge Healthcare
7.8. Genzyme Corp.
7.9. Merck & Co., Inc.
7.10. Ono Pharmaceutical Co.
7.11. Genzyme Corp.
7.12. GlaxoSmithKline Plc.
7.13. Pfizer Inc.
7.14. Roche Holding AG
7.15. Spectrum Pharmaceuticals Inc.
7.16. Sunesis Pharmaceuticals Inc.
7.17. Takeda Oncology
7.18. Teva Pharmaceuticals
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Actinium Pharmaceuticals Inc.
  • Affichem
  • Biogen Idec Inc.
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly And Co.
  • Ge Healthcare
  • Genzyme Corp.
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co.
  • Genzyme Corp.
  • GlaxoSmithKline Plc.
  • Pfizer Inc.
  • Roche Holding AG
  • Spectrum Pharmaceuticals Inc.
  • Sunesis Pharmaceuticals Inc.
  • Takeda Oncology
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll